Clinical trial
Taurolidine in Treating Patients With Recurrent or Progressive Glioma
NCT00022360 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00022360 |
|---|---|
| Title | Taurolidine in Treating Patients With Recurrent or Progressive Glioma |
| Official title | An Open-Label Dose-Ranging Study of the Safety of Taurolidine 2% Solution Administered Intravenously to Patients With Recurrent or Progressive High Grade Glioma |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | taurolidine |
| Start date | May 1, 2001 |
| Primary completion | Oct 1, 2001 |
| Completion | Oct 1, 2001 |
| First posted | Mar 19, 2004 |
| Last update posted | Jun 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: